PTPI vs. IMNN, HCWB, SNSE, FLGC, AIM, BGXX, HOTH, CRVO, WENA, and CSCI
Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Imunon (IMNN), HCW Biologics (HCWB), Sensei Biotherapeutics (SNSE), Flora Growth (FLGC), AIM ImmunoTech (AIM), Bright Green (BGXX), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), and COSCIENS Biopharma (CSCI). These companies are all part of the "pharmaceutical products" industry.
Petros Pharmaceuticals vs.
Imunon (NASDAQ:IMNN) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
Imunon has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
In the previous week, Imunon's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.
Imunon received 17 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users.
4.5% of Imunon shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Petros Pharmaceuticals' return on equity of -78.22% beat Imunon's return on equity.
Imunon currently has a consensus target price of $20.50, suggesting a potential upside of 2,186.67%. Given Imunon's stronger consensus rating and higher possible upside, equities analysts plainly believe Imunon is more favorable than Petros Pharmaceuticals.
Petros Pharmaceuticals has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Imunon beats Petros Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Petros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Petros Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PTPI) was last updated on 1/22/2025 by MarketBeat.com Staff
